Omeros (OMER) Other Non-Current Liabilities (2021 - 2026)
Omeros' (OMER) quarterly Other Non-Current Liabilities came in at $84.0 million in Q1 2026, up 1766.81% year-on-year from $4.5 million in Q1 2025, and up 1373.61% quarter-over-quarter from $5.7 million in Q4 2025.
Omeros (OMER) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Omeros has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $84.0 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $84.0 million, up 1766.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.0 million (up 1766.81% YoY), and the FY2025 annual result was $5.7 million, up 26.68% from the prior year.
- Other Non-Current Liabilities came in at $84.0 million for Q1 2026 at Omeros, up from $5.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $178.1 million in Q2 2025 to a low of $444000.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $2.1 million (2023), against an average of $27.7 million.
- Across the five-year window, Other Non-Current Liabilities plunged 60.18% in 2022 and soared 8428.83% in 2025, its largest moves.
- Omeros' Other Non-Current Liabilities stood at $444000.0 in 2022, then soared by 370.27% to $2.1 million in 2023, then soared by 115.57% to $4.5 million in 2024, then gained by 26.68% to $5.7 million in 2025, then soared by 1373.61% to $84.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $84.0 million (Q1 2026), $5.7 million (Q4 2025), and $152.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.03 Mn |
| Dec 31, 2025 | 5.70 Mn |
| Sep 30, 2025 | 152.53 Mn |
| Jun 30, 2025 | 178.08 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Jun 30, 2023 | 496,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 444,000.00 |
| Sep 30, 2022 | 999,000.00 |
| Jun 30, 2022 | 961,000.00 |
| Mar 31, 2022 | 922,000.00 |
| Dec 31, 2021 | 1.12 Mn |